Deseret Mutual Benefit Administrators Purchases 655 Shares of Bristol-Myers Squibb (NYSE:BMY)

Deseret Mutual Benefit Administrators lifted its stake in Bristol-Myers Squibb (NYSE:BMY) by 5.8% in the third quarter, Holdings Channel.com reports. The fund owned 11,981 shares of the biopharmaceutical company’s stock after purchasing an additional 655 shares during the period. Deseret Mutual Benefit Administrators’ holdings in Bristol-Myers Squibb were worth $620,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Montecito Bank & Trust boosted its stake in Bristol-Myers Squibb by 2.7% during the third quarter. Montecito Bank & Trust now owns 12,224 shares of the biopharmaceutical company’s stock valued at $632,000 after buying an additional 323 shares during the period. Principal Financial Group Inc. raised its position in Bristol-Myers Squibb by 4.4% during the third quarter. Principal Financial Group Inc. now owns 2,458,536 shares of the biopharmaceutical company’s stock valued at $127,205,000 after purchasing an additional 102,790 shares in the last quarter. Graypoint LLC increased its holdings in shares of Bristol-Myers Squibb by 29.4% in the third quarter. Graypoint LLC now owns 11,293 shares of the biopharmaceutical company’s stock worth $584,000 after buying an additional 2,563 shares during the period. Concurrent Investment Advisors LLC increased its holdings in shares of Bristol-Myers Squibb by 8.7% in the third quarter. Concurrent Investment Advisors LLC now owns 28,164 shares of the biopharmaceutical company’s stock worth $1,457,000 after buying an additional 2,255 shares during the period. Finally, Maia Wealth LLC purchased a new position in shares of Bristol-Myers Squibb in the third quarter worth about $211,000. 76.41% of the stock is owned by institutional investors.

Bristol-Myers Squibb Price Performance

Shares of NYSE BMY opened at $55.29 on Thursday. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $56.80. The firm has a market cap of $112.14 billion, a P/E ratio of -15.40, a PEG ratio of 13.14 and a beta of 0.44. The company has a 50 day moving average of $51.69 and a 200 day moving average of $46.72. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company had revenue of $11.89 billion during the quarter, compared to analyst estimates of $11.26 billion. During the same period in the previous year, the business earned $2.00 EPS. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. As a group, research analysts expect that Bristol-Myers Squibb will post 0.83 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Friday, October 4th were paid a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a yield of 4.34%. Bristol-Myers Squibb’s dividend payout ratio is presently -66.85%.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft reduced their price target on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a report on Tuesday, July 23rd. Jefferies Financial Group lifted their price objective on Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a research report on Wednesday, August 28th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $50.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, October 18th. TD Cowen lifted their price objective on Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Finally, BMO Capital Markets lifted their price objective on Bristol-Myers Squibb from $53.00 to $57.00 and gave the company a “market perform” rating in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $53.00.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, SVP Phil M. Holzer sold 700 shares of the business’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the completion of the sale, the senior vice president now directly owns 11,760 shares in the company, valued at approximately $654,091.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Samit Hirawat acquired 1,830 shares of Bristol-Myers Squibb stock in a transaction dated Friday, November 1st. The stock was purchased at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the purchase, the executive vice president now directly owns 62,109 shares of the company’s stock, valued at approximately $3,395,499.03. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Phil M. Holzer sold 700 shares of the company’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $55.62, for a total value of $38,934.00. Following the completion of the sale, the senior vice president now owns 11,760 shares of the company’s stock, valued at $654,091.20. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.09% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.